Description

Eptifibatide is a cyclic heptapeptide derived from rattlesnake venom, acting as a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor, the final common pathway in platelet aggregation. By inhibiting fibrinogen and von Willebrand factor binding, it prevents platelet cross-linking and thrombus formation ([DrugBank], [MedKoo], [ChemBook])

This high-purity (?99.29%) GMP-grade peptide is intended for laboratory research in thrombosis, platelet function, cardiovascular pharmacology, and anticoagulant drug development studies.

Product Specifications

Mechanism of Action & Research Applications

Eptifibatide functions by reversibly binding to platelet glycoprotein IIb/IIIa receptors, blocking the final step in platelet aggregation and clot formation. It is widely used in thrombosis research, platelet function assays, anticoagulant mechanism studies, and drug screening in cardiovascular models

Side Effects (for Research Context Only)

Experimental use of Eptifibatide in lab models may show:

• Dose-dependent inhibition of platelet aggregation

• Potential bleeding tendency in perfused models

• Transient hemodynamic changes under perfusion protocols

These effects are observed under controlled research conditions only.

Disclaimer

This product is for laboratory research use only, strictly not approved for clinical, human, or veterinary applications. Researchers must follow institutional safety guidelines when handling.